

AstraZeneca

VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) Reporting

In Accordance with the requirements set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) regulation, this is a notification of AstraZeneca's intent to engage in the wholesale importation of the prescription drug; FASENRA PEN™ (benralizumab) into the state of Vermont. Product is expected to be available in the market on October 28, 2019.

The Product and Pricing

| Branded Name | Generic Name | NDC | WAC Package Price | Effective Date |
|--------------|--------------|---------------|-------------------|----------------|
| Fasenra Pen | benralizumab | 00310-1830-30 | \$4,895.74 | 10/03/19 |